Solventum (SOLV) | Stock Overview & Key Data
Solventum Performance Comparison
Stock Range
Today's Range
Low: $72.01
High: $74.17
on August 22, 2025
52 Week Range
Low: $59.35
High: $85.92
on August 28, 2024
on February 26, 2025
All-Time High: $96.05 on March 25, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$12.9B
EPS
2.17
P/E Ratio (TTM)
34.45
Forward P/E
13.52
P/B Ratio
3.96
PEG Ratio
13.52
Div. Yield
N/A
ROE
10.66%
Beta
N/A
Debt to Equity
242.58
Financial Highlights
Profitability
Gross Margin
53.82%
Operating Margin
7.73%
Profit Margin
4.56%
Returns and Earnings
Return on Assets (TTM)
3.72%
Return on Equity (TTM)
10.66%
EBITDA
$1.3B
Net Income (TTM)
$379.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$48.08
Quarterly Revenue Growth (YoY)
2.70%
Quarterly Earnings Growth (YoY)
-42.20%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Solventum SOLV | 12.93B Large-cap | 3.01% | 0.89% | 1.25% | -3.55% | 11.59% | 19.79% | 5.75% | 5.75% |
| Intuitive Surgical ISRG | 168.44B Large-cap | -0.85% | -6.82% | -12.26% | -19.43% | -9.13% | -2.14% | 125.57% | 96.48% |
| Becton, Dickinson BDX | 56.36B Large-cap | 1.90% | 10.14% | 15.87% | -13.31% | -11.85% | -15.54% | -21.31% | -15.72% |
| Alcon ALC | 45.84B Large-cap | -6.49% | -7.49% | -4.78% | -8.15% | -1.71% | -14.68% | 22.83% | 42.20% |
| ResMed RMD | 42.22B Large-cap | 3.10% | 9.85% | 19.65% | 27.90% | 28.56% | 29.60% | 32.82% | 62.98% |
| West Pharmaceutical WST | 17.76B Large-cap | 0.74% | 13.30% | 18.96% | 12.19% | -24.48% | -18.14% | -18.41% | -8.74% |
Ownership & Short Interest
Insider Ownership
20.00%
Institutional Ownership
67.75%
Shares Short
4M
Short Ratio
4.82
Short % of Shares Outstanding
2.78%
Average 10-Day Volume
526K
Average 90-Day Volume
705K
Solventum Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Solventum would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SOLV's 52-week high and low?
- In the last 52 weeks, Solventum reached a high of $85.92 (on February 26, 2025) and a low of $59.35 (on August 28, 2024).
- What is the market cap and P/E ratio for SOLV?
- Curious about Solventum's size and valuation? Its market capitalization stands at 12.93B. When it comes to valuation, the P/E ratio (trailing twelve months) is 34.45, and the forward P/E (looking ahead) is 13.52.
- Does SOLV pay dividends? If so, what's the yield?
- As for dividends, Solventum isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Solventum's main competitors or similar companies to consider before investing?
When looking at Solventum, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Intuitive Surgical
ISRG168.44B Healthcare Medical Instruments & Supplies -2.14% 125.57% Becton, Dickinson
BDX56.36B Healthcare Medical Instruments & Supplies -15.54% -21.31% Alcon
ALC45.84B Healthcare Medical Instruments & Supplies -14.68% 22.83% ResMed
RMD42.22B Healthcare Medical Instruments & Supplies 29.60% 32.82% West Pharmaceutical
WST17.76B Healthcare Medical Instruments & Supplies -18.14% -18.41% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Solventum Corp? (e.g., ROE, Debt/Equity)
- To get a sense of Solventum's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.66%, the Debt to Equity ratio from the most recent quarter is 242.58, and its Gross Profit Margin stands at 53.82%.
- What is the recent revenue and earnings growth for SOLV?
- Looking at Solventum's growth, its revenue over the trailing twelve months (TTM) was $8B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.70%, and quarterly earnings saw a YoY growth of -42.20%.
- How much of SOLV stock is held by insiders and institutions?
- Wondering who owns Solventum stock? Company insiders (like executives and directors) hold about 20.00% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 67.75%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.